Company Profile

Razi Pharma LLC
Profile last edited on: 2/26/24      CAGE: 8MU73      UEI: EL1BYG75FMC5

Business Identifier: Improved therapeutic antibodies using a novel platform
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

526 Durand Drive Ne
Atlanta, GA 30307
   (404) 545-1972
Location: Single
Congr. District: 05
County: DeKalb

Public Profile

With a track record of having been CEO and/or founder of several other firms and Associate Vice President For Research and Director, Technology Transfer, the president of Razi Pharma brings a diversity of relavent experience to the table. Indicated as a viable business since 2019, the firm itself has a very limited online presence with management describing the firm as an innovative bio-pharmaceutical company dedicated to developing innovative vaccines and treatments for infectious diseases and novel immuno-oncology therapies.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $579,425
Project Title: F plus G RSV VLP Vaccine for Improved Safety and Efficacy

Key People / Management

  Vincent La Terza -- President

  Larry Anderson

  Vincent Laterza

Company News

There are no news available.